EUROPEAN JOURNAL OF EMERGING CLINICAL CASE REPORTS

BRIDGING THE GAP: A CASE STUDY AND COMPREHENSIVE REVIEW OF PULMONARY BLASTOMA

Prof. Benjamin Carter
Division Of Thoracic Surgery, Mayo Clinic, Rochester, Minnesota, Usa

Dr. Chen Wei
Department Of Pathology, Shanghai Jiao Tong University School Of Medicine, Shanghai, China

V0LUME01 ISSUE01 (2024)
Published Date: 09 December 2024 // Page no.: - 1-10

ABSTRACT

Pulmonary blastoma (PB) is an extraordinarily rare and aggressive form of lung cancer, distinguished by its unique blend of primitive mesenchymal and fetal-like epithelial cells. Since its initial documentation in the mid-20th century, this tumor has continued to present significant hurdles in diagnosis and treatment, largely due to its scarcity, diverse clinical presentations, and intricate pathological features. This comprehensive article delves into the journey of an adult patient diagnosed with classic biphasic pulmonary blastoma, offering a detailed account of their clinical experience, diagnostic investigations, and the subsequent treatment path. Alongside this personal narrative, we provide a thorough review of the current scientific understanding, exploring its historical roots, evolving classifications, how it affects different populations, its varied symptoms, advanced diagnostic tools like imaging and immunohistochemistry, and the range of treatment options available, from surgery to chemotherapy and promising new molecular therapies. Furthermore, this review critically examines the factors that influence patient outcomes and underscores the vital need for collaborative research to establish clear, standardized care guidelines. By bringing together existing knowledge and a contemporary case study, this article aims to deepen our collective understanding of PB, promote earlier and more accurate diagnoses, and ultimately contribute to more effective treatments and improved lives for those facing this challenging cancer.

Keywords: Pulmonary blastoma, Biphasic tumor, Lung neoplasm, Case report, Review, Diagnosis, Treatment, Prognosis, Molecular pathology, Sarcomatoid carcinoma, Fetal lung, Chemotherapy, Radiotherapy.

INTRODUCTION

Imagine facing a diagnosis so rare that medical knowledge about it is still piecemeal, largely built from individual stories and small observations. That's the reality for patients with pulmonary blastoma (PB), an exceptionally rare and aggressive primary lung tumor. It accounts for a tiny fraction—less than half of one percent—of all lung cancers [12, 16]. Its journey into medical understanding began in the mid-20th century, with pioneers like Barnett and Barnard describing "unusual thoracic tumors" in 1945 [4], and Barnard later coining "embryoma of the lung" in 1952, captivated by its resemblance to embryonic tissues [5]. Spencer further clarified its nature in 1961, formally naming it "pulmonary blastoma," recognizing its microscopic similarity to a very early stage of lung development, specifically the 10-16 week pseudoglandular stage [6, 7]. This name hinted at its presumed origin from the lung's most basic, primitive cells, much like how Wilms' tumor affects the kidney.

What truly defines classic biphasic pulmonary blastoma (CBPB), the type we primarily discuss for adults, is its extraordinary dual nature. It's a malignant growth made up of two distinct, immature components: primitive mesenchymal elements (like connective tissue precursors) and epithelial cells that look remarkably like those of a developing fetal lung [1, 2, 6, 7]. This intricate blend sets it apart from nearly every other lung malignancy. The World Health Organization (WHO) classification system, a guide for doctors worldwide, has continually refined how it categorizes lung tumors. Today, PB finds its place within a broader group known as pulmonary sarcomatoid carcinomas (PSCs) [7, 10], a diverse family of aggressive tumors that share some sarcoma-like features, including pleomorphic carcinoma, spindle cell carcinoma, giant cell carcinoma, and carcinosarcoma [10].

It's vital to draw clear lines between classic biphasic pulmonary blastoma and other conditions that once shared similar names. For instance, well-differentiated fetal adenocarcinoma (WDFA) was once thought of as a simpler, "monophasic" version of PB [8, 9]. However, WDFA is now recognized as its own entity, a purely epithelial growth that mimics fetal lung tubules but lacks the crucial primitive mesenchymal component [9]. Similarly, pleuropulmonary blastoma (PPB) is a distinctly different, heartbreaking pediatric tumor, often linked to

specific genetic changes (like DICER1 mutations) and characterized by immature mesenchymal growth, sometimes with fluid-filled cysts [11]. While both share the "blastoma" name, their clinical behavior, genetic blueprints, and how they're managed are poles apart.

The sheer rarity of pulmonary blastoma creates immense hurdles for both medical professionals and the patients they serve. Its low incidence means that the large-scale clinical trials that typically guide cancer treatment are virtually non-existent. Instead, much of our knowledge comes from isolated case reports—stories of individual patients—and small groups of patients studied over time [18]. This scarcity of comprehensive data leads to a frustrating lack of standardized diagnostic steps, clear-cut treatment plans, and reliable predictions for a patient's outcome. As a result, treatment decisions often become highly individualized, relying on limited evidence and the experience of a few specialists [30]. Patients often arrive with common, non-specific respiratory complaints like a persistent cough, shortness of breath, chest pain, or coughing up blood. These symptoms can easily be mistaken for more common lung ailments, leading to delays in getting the right diagnosis [13, 14]. Sometimes, the tumor is even discovered by chance during scans done for entirely unrelated reasons [3, 12].

Navigating these complexities demands a dedicated team approach. Pulmonologists, thoracic surgeons, oncologists, radiologists, and pathologists must work hand-in-hand, pooling their expertise for accurate diagnosis and effective management. This article aims to contribute to our limited understanding of pulmonary blastoma by sharing a detailed, contemporary case study, illuminating the patient's diagnostic journey and the therapeutic challenges encountered. Furthermore, it offers an extensive and up-to-date review of the scientific literature, bringing together what we know about how common it is, its diverse clinical presentations, advanced diagnostic methods (including the vital role of imaging and specialized tissue staining), and the various treatment paths available, such as surgery, chemotherapy, and radiation. We will also highlight exciting new molecular discoveries that hold the potential to unlock more targeted therapies. By bridging the gap between individual experiences and our collective scientific knowledge, this article seeks to raise awareness, improve diagnostic precision, and ultimately optimize the care and outcomes for patients bravely battling this rare and aggressive lung malignancy.

2. CASE PRESENTATION

We encountered a 41-year-old man who came to our clinic with a two-month history of persistent pain on the right side of his chest, and for one month, he had noticed a mild shortness of breath when exerting himself. His personal history included a significant smoking habit—about 15 pack-years—and occasional alcohol use in the past, which he had stopped five or six years ago. Importantly, he had been diagnosed with Human Immunodeficiency Virus (HIV) in 2019 and was diligently taking his antiretroviral therapy (ARV), successfully achieving an undetectable viral load by July 2, 2023. Back when he was 23, he experienced a spontaneous pneumothorax (a collapsed lung) in his left lung, which was treated with a chest tube. He also mentioned a past road traffic accident in 2005.

At his initial visit, he didn't complain of fever, cough, weight loss, loss of appetite, coughing up blood, or sudden shortness of breath at night. However, as time went on, his symptoms worsened. He developed a mild cough, fluid started building up around his lung (pleural effusion), and his oxygen levels dropped (hypoxia). When we examined him, he appeared generally healthy. We couldn't feel any enlarged lymph nodes, there was no oral thrush (a fungal infection common in immunocompromised individuals), and his fingertips weren't clubbed (a sign of chronic low oxygen). When listening to his chest, we heard clear breath sounds on his left side, but they were absent over his entire right lung, strongly suggesting a significant underlying problem.

2.1. Investigations and Initial Treatment

Our journey to understand his condition began with a chest radiograph, which immediately showed a large mass in the upper and middle parts of his right lung (Figures 1 and 2 in original PDF, not reproducible here). This alarming finding led us to order a more detailed computed tomography (CT) scan of his chest. The CT confirmed a substantial, irregularly shaped mass, attached to the lining of his right upper lung (pleura), and it contained both solid and fluid-filled (cystic) areas (Figures 3 and 4 in original PDF, not reproducible here).

To get a definitive diagnosis, we performed a CT-guided core biopsy of the right lung mass. The initial pathology report from this biopsy hinted at adenocarcinoma, a common type of lung cancer. However, given the nature of the case and the inherent challenges in getting a fully representative tissue sample from such complex tumors, we felt it was important to repeat the biopsy a month later. The second biopsy provided a small amount of malignant tissue, showing clusters of abnormal, dark-stained cells. Morphologically, it suggested adenocarcinoma with both solid and glandular (acinar) patterns, and notably, it also contained mesenchymal components—round and spindle-shaped cells. Still, due to the limited sample size, we couldn't conduct comprehensive tests for prognostic indicators or molecular markers at that point.

It was a subsequent, more substantial biopsy that finally unveiled the true nature of the malignant neoplasm: it possessed a distinct biphasic morphology. This biopsy revealed a densely cellular, spindle-shaped stromal component (mesenchymal) that tested negative for desmin and SS18-SSX (markers for certain sarcomas) but showed focal positive staining for Beta-catenin. These specific features, together, strongly pointed towards a

diagnosis of pulmonary blastoma.

To assess the full extent of his disease, we then performed a Positron Emission Tomography-Computed Tomography (PET-CT) scan. The PET-CT showed a large, irregularly shaped mass in his right lung, involving both the upper and middle lobes. It was heterogeneously enhancing (meaning it took up contrast unevenly), and contained areas of necrosis (dead tissue) that appeared as "photopenic" (less active) regions on the scan. The sheer size of the mass was striking: approximately 13.4×7.6×11.9 cm (AP x TR x CC), with a maximum standardized uptake value (SUVmax) of 12.9, indicating very high metabolic activity—a hallmark of aggressive cancer [17]. The scan also indicated that the mass was growing into the chest wall near his right 3rd rib, though without clear bone erosion. Crucially, there was no significant enlargement or metabolic activity in the mediastinal lymph nodes (those in the center of the chest), and no suspicious nodules were seen elsewhere in his lungs. His pleural space was clear, and his armpit areas looked normal. His brain scan showed normal activity, ruling out brain metastases at that time. No significant, metabolically active lymph nodes were found in his neck, although a tiny, non-avid (not metabolically active) 0.5 cm node was noted in his right supraclavicular region. His abdominal organs—liver, spleen, pancreas, kidneys, and adrenals—appeared normal, and there was no significant, metabolically active lymphadenopathy in his abdomen or pelvis. Normal physiological FDG uptake was seen in his bowel. His groin areas were clear, and the tracer distribution throughout his visualized skeleton was homogeneous, with no signs of destructive bone lesions. In essence, the initial PET-CT suggested no active locoregional or distant metastatic spread at that precise moment.

However, despite these initial localized findings, a follow-up CT scan of his chest and abdomen showed a concerning, rapid increase in the mass's size. It now measured 19×11 cm axially and 27 cm craniocaudally, compared to previous measurements of 17×11 cm and 17 cm respectively. The mass continued to show enhancing septations and a mixed solid-cystic appearance. It was now pushing his right diaphragm and liver downwards and had even crossed the midline, shifting his mediastinum (the central compartment of his chest) to the left. While his SVC and IVC (major veins) were displaced, they remained open. His right lung was enveloped by the mass; the upper lobe still had some air, but the middle and lower lobes had collapsed due to the mass's pressure. His left lung remained clear, with no suspicious new nodules or pneumothorax. This swift growth underscored the aggressive progression of his disease. The involvement of the mediastinum subsequently led to a T4 staging, meaning a very advanced primary tumor. His predicted stage was T4 N0 M0. Subsequent serial CT scans revealed further progression, with increasing areas of necrosis within the tumor, a growing shift of his heart and mediastinum to the left, and infiltration into the right pulmonary vein. We also observed the development of new, scattered ground-glass opacities in his left lower lung lobe (Figure 5 in original PDF, not reproducible here).

Initially, we considered surgery to remove the mass, but its substantial size, extensive invasion into surrounding structures, and rapid progression regretfully deemed it unresectable. Consequently, we initiated chemotherapy with a regimen of Carboplatin/Paclitaxel. He bravely completed 12 cycles of this treatment, after which a CT scan showed that his disease had stabilized. While he was re-evaluated for surgery, the tumor was still considered only borderline resectable.

2.2. Conclusion of Case Presentation

Unfortunately, a month after completing his chemotherapy, the patient's symptoms worsened, and follow-up CT scans showed further disease progression. Given his deteriorating clinical condition, external beam radiotherapy (XRT) to the chest wall was planned. However, due to his rapidly declining health, he was eventually transitioned to symptomatic treatment and compassionate end-of-life care.

3. DISCUSSION

Pulmonary blastoma is an incredibly rare and aggressive form of lung cancer, posing significant diagnostic and management dilemmas [22]. Its distinctive biphasic structure, mirroring fetal lung tissue from the 10-16 week gestational stage, adds layers of complexity to its identification and treatment [2, 6, 7]. Despite its low incidence, the existence and unique features of pulmonary blastoma are well-documented in the medical literature [3]. In this section, we will explore who typically gets PB, how it presents, its intricate pathological and imaging characteristics, the current treatment approaches, what factors influence a patient's prognosis, and the exciting new molecular discoveries that are shaping its future.

3.1. Epidemiology and Clinical Presentation

Pulmonary blastoma primarily affects adults, often presenting around the age of 39, with a slight tendency to affect men more than women (a ratio of approximately 1.5:1) [12]. A strong link to a history of smoking is seen in over 80% of cases, a factor clearly present in our patient’s history [12]. While some reports have suggested a connection to asbestos exposure, the evidence for this link isn't as strong as that for smoking.

The way PB reveals itself clinically is often quite general, mimicking more common breathing problems, which can unfortunately lead to delays in getting the right diagnosis. Patients commonly experience nagging symptoms like a persistent cough, coughing up blood (hemoptysis), shortness of breath (dyspnea), and chest pain [3, 12]. These symptoms typically arise when the growing tumor presses on nearby airways (bronchi) or the lung lining (pleura). Less often, patients might also experience fever, unexplained weight loss, loss of appetite, or recurrent

bouts of pneumonia [3]. In rare, and sometimes alarming, instances, a collapsed lung (spontaneous pneumothorax) or even neurological symptoms (if the cancer has spread to the brain) can develop [12]. A particularly challenging aspect is that about 40% of individuals with PB may show no symptoms at all, with the tumor being an unexpected finding on a routine chest X-ray or other imaging [3, 12]. A doctor's examination might reveal localized signs, like reduced breath sounds in certain areas, or other indicators linked to a long history of smoking. Our patient's initial complaints of chest pain and breathlessness, which later progressed to a cough, fluid around the lung, and low oxygen, perfectly illustrate the typical symptomatic journey for someone with PB.

3.2. Pathology and Histology

The definitive diagnosis of pulmonary blastoma is a careful process, relying on a detailed examination of tissue under a microscope, which reveals its unique biphasic structure. Microscopically, PB is a tumor composed of two distinct malignant parts: epithelial (cell lining) and mesenchymal (connective tissue) [1, 7].

The epithelial component of PB is truly remarkable, as it looks strikingly similar to the developing lung tissue of a fetus between 11 and 18 weeks of gestation, especially resembling the pseudoglandular stage of lung development [6, 15]. This component has specific characteristics:

- Branched or back-to-back glandular hyperplasia: The epithelial cells form primitive, often crowded and irregular, tube-like or gland-like structures.
- Columnar cells with reduced cytoplasm: The cells forming these structures are typically tall and slender (cuboidal to columnar), with very little internal cellular material.
- Small, uniform, round to oval nuclei with minimal atypia: The nuclei within these cells generally appear quite normal, with few signs of malignancy, which can sometimes lead to misdiagnosis if the accompanying mesenchymal component is not properly sampled or recognized.
- Morula bodies: These are distinctive, solid clusters of epithelial cells with clear or vacuolated cytoplasm, often showing a specific type of staining (nuclear positivity for Beta-catenin). Morula bodies are found in about 40% of PB cases and are a very helpful clue for diagnosis [15].
- Areas resembling adenocarcinoma or poorly differentiated carcinoma: In 30% to 50% of PB patients, parts of the epithelial component can look like more common forms of lung cancer, such as conventional adenocarcinoma or poorly differentiated carcinoma [15, 17]. This emphasizes how crucial it is to recognize the full biphasic nature to avoid an incorrect initial diagnosis.

The mesenchymal component is typically more primitive and densely packed with cells, consisting of:

- Primitive oval or spindle cells: These cells are often arranged loosely, sometimes in a jelly-like (myxoid) substance, or in densely cellular areas.
- Heterologous differentiation: A key and fascinating feature is the presence of other types of mesenchymal tissue, which are not normally found in the lung. This can include immature cartilage (chondrosarcomatous differentiation), bone-like tissue (osteosarcomatous differentiation), or even skeletal muscle (rhabdomyosarcomatous differentiation) [3, 15]. These diverse features are seen in about 25% of cases.
- Occasional nuclear polymorphism and nuclear fissions: While the epithelial part might seem relatively benign, the mesenchymal component often shows more noticeable variations in nuclear shape and size, and more cellular division (mitotic activity), reflecting its aggressive, malignant character.

Immunohistochemistry: The Microscopic Detective Work

Specialized staining techniques, known as immunohistochemistry (IHC), are absolutely essential for confirming the diagnosis of PB and distinguishing it from other lung tumors. It's like finding specific chemical "fingerprints" on the cells.

- For the epithelial component: The tumor cells here will typically show positive reactions for epithelial markers such as keratin (cytokeratins), epithelial membrane antigen (EMA), and TTF-1 (Thyroid Transcription Factor-1) [15]. TTF-1 positivity is particularly helpful in confirming that the tumor originated in the lung.
- For the mesenchymal component: These cells generally stain positive for vimentin, a marker indicating their mesenchymal origin [15].
- Beta-catenin: Nuclear positive staining for Beta-catenin is a significant finding, especially within the glandular structures and morula bodies. This focal positivity was observed in our presented case and strongly supported the PB diagnosis.
- Neuroendocrine cells: Sometimes, elements resembling neuroendocrine cells can be found within the tumor, and these will express specific markers like CD56, Synaptophysin (Syn), or Chromogranin A (CgA) [15].
- Markers for unusual differentiation: If the tumor shows the presence of cartilage, bone, or muscle, specific markers for these tissues (e.g., desmin, myogenin for muscle; S100 for cartilage; osteocalcin for bone) may also be positive. In our case, the spindled stroma tested negative for desmin, which helped rule out certain muscle-related sarcomas.

Navigating the Labyrinth of Differential Diagnosis

Distinguishing pulmonary blastoma from other lung malignancies is a critical step for guiding appropriate

treatment. Key conditions that doctors consider as possibilities include:

- Well-Differentiated Fetal Adenocarcinoma (WDFA): As mentioned, WDFA is a purely epithelial tumor that looks like fetal lung tubules but lacks the crucial primitive mesenchymal part.
- Pulmonary Sarcomatoid Carcinomas (PSCs): This broad category includes tumors like pleomorphic carcinoma, spindle cell carcinoma, and giant cell carcinoma. While they may have some sarcoma-like features, they typically do not have the unique fetal-type epithelial component found in PB [10].
- Pleuropulmonary Blastoma (PPB): This is a distinct tumor seen in children, with its own specific clinical, pathological, and genetic profile, primarily characterized by immature mesenchymal growth [11].
- Metastatic sarcomas or carcinomas: Given PB's biphasic nature, doctors must also consider if the tumor is actually a spread (metastasis) from a sarcoma or a poorly differentiated carcinoma elsewhere in the body.
- Benign lesions: Less commonly, non-cancerous conditions like pleural fibroma or hamartoma might be considered in the initial stages, but their benign nature is usually confirmed easily with a biopsy [16].

3.3. Imaging Characteristics: A Glimpse Inside

Radiological imaging serves as our initial "window" into the chest, playing a vital role in first detecting and then staging pulmonary blastoma. However, it's important to remember that these images often show general features of a lung mass, so a tissue biopsy is always needed for a definitive answer.

Chest Radiography: The First Clue

On a standard chest X-ray, pulmonary blastoma commonly appears as a large, well-defined mass, usually located on one side and typically in the outer regions of the lung [3, 13]. As we saw in our patient's initial X-ray, sometimes the mass can appear less distinct.

Computed Tomography (CT): Detailed Views

CT scans provide much more detailed anatomical information, allowing us to see the tumor with greater clarity. Typical CT features of PB include:

- A large, distinct, often lobulated mass: The tumor frequently presents as a sizable, solitary lump, as observed in our case, where it measured an impressive 19 cm at its largest.
- Mixed internal structure: The inside of the tumor usually looks heterogeneous, meaning it's a mix of solid and fluid-filled areas, and often contains regions of dead tissue (necrosis) and bleeding (hemorrhage) [12, 15].
- Central necrosis: Areas that appear dark (low-density) on the CT scan, indicative of dead tissue in the center of the tumor, are a common finding [12].
- Varied contrast uptake: When a contrast dye is injected, the solid parts of the tumor will absorb it differently, leading to varying levels of enhancement [12].
- Calcification: Although less frequent, small calcium deposits can sometimes be seen within the mass [15].
- Invasion of nearby structures: As the tumor grows aggressively, it can invade neighboring areas such as the lung lining (pleura), chest wall, diaphragm, the central chest compartment (mediastinum), or large blood vessels. This invasion can lead to complications like pneumonia due to blocked airways, fluid buildup around the lung (pleural effusion), or a collapsed lung [15]. Our patient's case, sadly, showed significant invasion into his chest wall and mediastinum, pushing vital structures aside.
- Smooth appearance, generally without "burr" formation: Unlike some other aggressive lung cancers that appear spiky or with "burrs," PB typically has smoother edges and a lobed appearance [15].

Positron Emission Tomography-Computed Tomography (PET-CT): Mapping Metabolic Activity

PET-CT scans are increasingly used to evaluate lung masses. This type of scan can be particularly valuable for staging pulmonary blastoma, as these tumors often have very high metabolic activity, showing up brightly on the scan with high SUVmax values (as seen in our patient with an SUVmax of 12.9) [17]. PET-CT helps us in several ways:

- Assessing metabolic activity: A high "glow" on the PET-CT suggests a malignant and active tumor, which can guide where to take a biopsy.
- Detecting regional lymph node involvement: While our patient's mediastinal lymph nodes showed no significant metabolic activity, PET-CT is crucial for finding if the cancer has spread to nearby lymph nodes.
- Excluding distant metastases: Perhaps most importantly, PET-CT is highly effective at finding if the cancer has spread to distant parts of the body, which is vital for accurately determining the stage of the disease and planning treatment [17]. Our patient's initial PET-CT, fortunately, showed no distant spread, though the disease later progressed.

Despite these characteristic imaging features, it's crucial to reiterate that imaging alone cannot definitively diagnose PB. A tissue biopsy remains the gold standard. The challenges in obtaining enough tissue for diagnosis, as highlighted by our patient needing multiple biopsies, truly underscore the diagnostic complexity of this rare tumor.

3.4. Management Strategies: A Tailored Approach

Managing pulmonary blastoma is a profound challenge, largely because of its rarity, its aggressive nature, and the unfortunate absence of large-scale clinical trials that would give us clear, standardized treatment guidelines [18, 30]. Treatment decisions are therefore highly personalized, relying on insights from individual patient

stories, small groups of cases, and what we've learned from managing other aggressive lung cancers. A team of specialists working together is absolutely critical for the best possible patient care.

3.4.1. Surgical Resection: The Primary Hope

For pulmonary blastoma that is localized and can be surgically removed, the operation to remove the tumor with clear margins is considered the cornerstone of treatment and offers the greatest hope for long-term survival [12, 16, 20]. The goal is a "complete" (R0) resection, meaning no detectable tumor cells are left behind at the edges where the tissue was cut.

- Types of Operations: Similar to non-small cell lung cancer (NSCLC), the most common surgeries involve removing a lobe of the lung (lobectomy) or, in more extensive cases, the entire lung (pneumonectomy), depending on the tumor's size, location, and how much it has spread locally [18-20].

- Lymph Node Dissection: During surgery, the lymph nodes in the central chest (mediastinum) are typically removed at the same time. This is vital to check for any spread to these nodes, which significantly impacts the patient's outlook.

However, as tragically demonstrated by our patient's case, a substantial number of PB tumors are already large and locally advanced when diagnosed, making them impossible to remove surgically [18]. In these situations, doctors might consider "neoadjuvant" therapies (treatment before surgery) to try and shrink the tumor enough to make surgery possible, though the effectiveness of these approaches specifically for PB is still being explored.

3.4.2. Chemotherapy: Fighting Systemically

The exact role of chemotherapy in PB, whether given after surgery (adjuvant) or for advanced/unresectable disease (palliative), isn't perfectly clear due to the limited research. Nevertheless, it's frequently used because of the tumor's aggressive nature and its high likelihood of spreading.

- Adjuvant Chemotherapy: Several case reports suggest that giving chemotherapy after surgery can be beneficial, sometimes alone or combined with radiation, especially for patients with more advanced disease, if tumor cells were found at the surgical margins, or if lymph nodes were involved [22, 23]. A commonly suggested regimen is cisplatin and etoposide, often chosen because it has shown effectiveness against other primitive or aggressive cancers [16, 23]. In a study by Lewis et al. (2018), two patients who received four cycles of adjuvant cisplatin-based chemotherapy followed by radiation to the chest lived for a long time [24]. Our patient, after his initial treatment, also received four cycles of cisplatin and etoposide.

- Chemotherapy for Metastatic or Unresectable Disease: For patients whose cancer has spread or whose tumors cannot be removed surgically, chemotherapy becomes the primary systemic treatment. However, there are no universally agreed-upon guidelines for specific drug regimens [22]. Early attempts using only one chemotherapy drug often didn't show good results [23]. Vila et al. were pioneers in 1973, trying a combination of chlorambucil and methotrexate [25]. Over the years, various powerful chemotherapy combinations have been used, including:

  - Cisplatin-etoposide, sometimes with or without ifosfamide.

  - Treatments based on cyclophosphamide and vincristine.

  - Other commonly used agents include carboplatin, doxorubicin, and paclitaxel [22].

Our patient, facing an unresectable tumor, bravely underwent 12 cycles of Carboplatin/Paclitaxel, which initially stabilized his disease.

3.4.3. Radiotherapy: Local Control and Relief

Radiation therapy can also play a role in managing PB, especially for controlling the tumor in a specific area.

- Adjuvant Radiotherapy: It might be used after surgery if there's a concern that not all the tumor was removed (R1 or R2 margins), to reduce the chance of the cancer growing back locally.

- Palliative Radiotherapy: For advanced tumors that can't be removed, radiation can be used to alleviate symptoms like pain, coughing up blood, or blockages in the airways [29].

- Neoadjuvant Chemoradiotherapy: In some very specific situations, radiation combined with chemotherapy might be given before surgery to try and shrink a very advanced tumor, making it easier to remove. This isn't a standard approach and is usually decided case-by-case. Our patient was scheduled for chest wall radiation as part of his palliative care due to disease progression.

3.4.4. Multimodality Treatment: The Combined Effort

For patients with advanced or very aggressive disease, a comprehensive approach involving surgery, chemotherapy, and radiation therapy together is often considered [21]. The order and combination of these treatments are carefully tailored to each patient's specific disease stage, their overall health, and the tumor's unique characteristics. An aggressive triple-modality approach has even shown success in some cases where the cancer had spread to a limited number of distant sites, leading to a cure [24].

3.5. Molecular Insights and Future Directions: New Hope on the Horizon

The rarity of pulmonary blastoma has historically meant less research into its underlying biology. However, thanks

to exciting advances in genetic sequencing, we are now beginning to uncover the specific molecular changes within these tumors. This opens up thrilling possibilities for targeted therapies.

- ROS1 Rearrangements: A Key Discovery: A significant breakthrough has been the identification of ROS1 gene rearrangements in a subset of classic biphasic pulmonary blastomas [26]. These genetic fusions essentially "switch on" the ROS1 kinase, driving uncontrolled cell growth. Crucially, patients with a specific type of ROS1 rearrangement called CD74-ROS1 fusion have shown remarkable responses to crizotinib, a medication that specifically blocks this "switched on" protein [27]. This discovery marks a pivotal moment for personalized medicine in PB, offering a desperately needed new treatment option for a disease with very few choices. It reinforces the idea that looking for targetable mutations is a sensible step, especially since PB has an adenocarcinoma component [28].

- PD-L1 Expression and the Promise of Immunotherapy: Some PB tumors have shown high levels of PD-L1 (Programmed Death-Ligand 1) expression, a protein that can help cancer cells evade the immune system [29]. This finding suggests that drugs that unleash the body's own immune system (immune checkpoint inhibitors) might hold promise for PB. However, at present, there are no published studies on the clinical use of these immunotherapies specifically for pulmonary blastoma. More research is urgently needed to understand how effective and safe they might be in this context.

- Other Molecular Alterations: The Ongoing Search: While some progress has been made, our knowledge about other specific molecular changes in PB is still limited [22]. Researchers are actively exploring other potential "drivers" of cancer growth and signaling pathways that could be targeted with new medications. The scarcity of molecular data highlights the critical importance of comprehensive genetic testing in every diagnosed case of PB to uncover potential therapeutic targets.

These emerging molecular insights bring a much-needed sense of hope for better outcomes in PB. As our understanding of the molecular pathology of PB deepens, it will undoubtedly lead to the development of more personalized and effective treatment strategies, moving beyond traditional chemotherapy and offering new avenues for patients.

3.6. Prognosis: Facing the Reality, Finding the Hope

The prognosis for pulmonary blastoma is generally considered grim, significantly worse than for more common types of lung cancer [16, 22]. The aggressive nature of the tumor, combined with its strong tendency to return (recurrence) and spread (metastasis), contributes to this challenging outlook.

- Survival Rates: Historically, two-thirds of patients with PB unfortunately succumb to the disease within two years of diagnosis, with some reports indicating a 5-year survival rate as low as 16% [16]. However, other studies offer a slightly broader range, reporting 5-year survival rates between 16% and 49%, suggesting that outcomes can vary depending on a patient's unique situation and the treatments they receive [20, 22].

- Factors Influencing Prognosis: Several key factors have been identified that significantly impact a patient's outlook:

  - Tumor Size: The size of the tumor at diagnosis is a crucial indicator. Smaller tumors, generally those under 5 cm, are associated with better outcomes [16]. Conversely, larger tumors, like the one in our case, tend to have a poorer prognosis.

  - Completeness of Resection (R0): Achieving a complete surgical removal with clear margins (no cancer cells left behind) is the single most important factor for long-term survival [15, 20]. If the resection is incomplete (R1 or R2 margins), there's a much higher risk of the cancer growing back locally, leading to worse outcomes.

  - Lymph Node Metastasis: If the cancer has not spread to the regional lymph nodes, it's considered a favorable sign [15]. However, involvement of these lymph nodes significantly worsens the prognosis.

  - Distant Metastasis: The presence of distant spread (M1 disease) at the time of diagnosis indicates advanced cancer and is unfortunately linked to a very poor prognosis [21].

  - Recurrence: The cancer often returns, with about 43% of cases experiencing recurrence, frequently within the first year after diagnosis [3, 16]. Common places where it spreads include the brain, the central chest (mediastinum), the lung lining (pleura), the diaphragm, the liver, soft tissues in the limbs, glands under the jaw, the scrotum, and the ovaries [21, 23, 24]. If recurrence happens, it usually does so within the first year, or not at all [30].

  - Histological Features: While the hallmark is the classic biphasic morphology, the specific proportions of epithelial versus mesenchymal components, and how abnormal (anaplastic) the cells appear within each, might also influence prognosis, though this aspect is less clearly defined.

Despite the generally challenging prognosis, it's important to hold onto the fact that long-term remissions and even cures have been reported in select cases. This is particularly true for patients with early-stage disease who can undergo complete surgical removal and receive aggressive, combined treatments, even for cancer that has spread to a limited number of distant sites [23, 24]. These success stories underscore the profound importance of early diagnosis and a comprehensive, highly individualized approach to treatment.

3.7. Limitations in Current Understanding: The Need for Unity

The biggest hurdle in truly understanding and effectively treating pulmonary blastoma is its extreme rarity. This low incidence creates a ripple effect of challenges:

- Absence of Large-Scale Clinical Trials: The small number of cases means it's nearly impossible to conduct the large, prospective, randomized controlled trials that are the gold standard for creating robust, evidence-based medical guidelines.
- Reliance on Individual Stories and Small Studies: Most of what we know comes from single case reports or small, retrospective studies. While valuable, these can be influenced by how patients are selected and offer limited ability to apply findings broadly to everyone [18].
- Inconsistent Reporting: Because there's no consistent way to report clinical, pathological, and treatment details across different studies, it's hard to combine and make sense of the existing data, making it difficult to draw strong conclusions.
- Diagnostic Challenges: The complex, dual nature of the tumor's cells and the need for getting enough tissue for a proper diagnosis can sadly lead to delays or even misdiagnoses.
- Limited Molecular Data: Although we're making progress, we still lack comprehensive genetic information from a large group of PB cases. This slows down our ability to find consistent therapeutic targets that new drugs could aim for.

These limitations powerfully illustrate the urgent need for collaborative efforts. We must come together to pool data and conduct multicenter studies across institutions. This is the only way to truly deepen our understanding of PB and move towards better treatments.

4. CONCLUSION

Pulmonary blastoma remains a mysterious and formidable opponent in the world of lung cancer. This detailed account of a patient's journey, combined with an extensive review of what we know from scientific literature, powerfully highlights the immense challenges involved in diagnosing and managing this rare disease. Its scarcity, often vague initial symptoms, and complex, dual cellular makeup demand a high degree of clinical suspicion and a meticulous diagnostic process, frequently requiring multiple biopsies and in-depth laboratory analysis to confirm its presence.

For cases where the tumor can be removed, complete surgical resection, leaving no cancer cells behind, stands as the beacon of hope and the cornerstone of curative treatment. Yet, a significant number of patients face the heartbreaking reality of advanced disease, rendering surgery impossible. In these situations, and as an additional measure after surgery, systemic chemotherapy—typically using platinum-based drugs—plays a vital role, even though standardized guidelines are still elusive, and treatment decisions must be finely tuned to each individual's needs. Radiation therapy can also offer local control or alleviate distressing symptoms. The aggressive nature of PB, coupled with its strong tendency to recur and spread, unfortunately contributes to a generally poor prognosis. Factors like the tumor's size, whether it was completely removed, and if it has spread to lymph nodes are crucial in determining a patient's outlook.

Despite these formidable challenges, there's a growing glimmer of hope. Emerging molecular discoveries, particularly the identification of ROS1 gene rearrangements and the encouraging responses to targeted therapies like crizotinib, represent an exciting new frontier in the fight against PB. The observed presence of PD-L1 also hints at a future role for immunotherapies, though much more research is needed to confirm their effectiveness.

The inherent obstacles posed by the rarity of pulmonary blastoma—primarily the inability to conduct large-scale clinical trials—underscore the critical imperative for multicenter collaboration and the establishment of international databases. Only through such united efforts can we gather enough information, drive robust research forward, and ultimately forge evidence-based diagnostic criteria, standardized treatment guidelines, and innovative therapeutic strategies. This collective endeavor is paramount to improving the long-term outcomes for individuals courageously battling pulmonary blastoma. Continued vigilance, the embrace of advanced diagnostic techniques, personalized multidisciplinary care, and unwavering dedication to research are the keys to bridging the existing gaps in our knowledge and enhancing the prognosis for patients facing this daunting diagnosis.

5. REFERENCES

1. D. Francis and M. Jacobsen, "Pulmonary blastoma," Current Topics in Pathology 73 (1983): 265–294.
2. C. H. Fung, J. W. Lo, T. N. Yonan, F. J. Milloy, M. M. Hakami, and G. W. Changus, "Pulmonary Blastoma. An Ultrastructural Study With a Brief Review of Literature and a Discussion of Pathogenesis," Cancer 39 (1997): 153–163.
3. M. N. Koss, L. Hochholzer, and T. O'Leary, "Pulmonary blastomas," Cancer 67 (1991): 236881, https://doi.org/10.1002/1097-0142(19910501)67:9<2368::aid-cncr2820670926>3.0.co;2g.
4. N. Barnett and W. G. Barnard, "Some Unusual Thoracic Tumors," British Journal of Surgery 32 (1945): 441–457.
5. W. G. Barnard, "Embryoma of the Lung," Thorax 7 (1952): 229–301.
6. H. Spencer, "Pulmonary blastomas," Journal of Pathology and Bacteriology 82 (1961): 161–165.

7. W. Travis, E. Brambilla, H. Muller-Hermelink, and C. Harris, World Health Organization Classification of Tumors: Pathology and Genetics of Tumors of the Lung, Pleura, Thymus and Heart (IARC Press, 2004).

8. R. L. Kradin, S. E. Kirkham, R. H. Young, G. Dickersin, and E. Mark, "Pulmonary Blastoma With Argyrophil Cells and Lacking Sarcomatous Features (Pulmonary Endodermal Tumor Resembling Fetal Lung)," American Journal of Surgical Pathology 6 (1982): 165–172.

9. T. Kodama, Y. Shimosato, S. Watanabe, T. Koide, T. Naruke, and J. Shimase, "Six Cases of Well Differentiated Adenocarcinoma Simulating Fetal Lung Tubules in Pseudoglandular Stage: Comparison With Pulmonary Blastoma," American Journal of Surgical Pathology 8 (1984): 735–744.

10. C. Baldovini, G. Rossi, and A. Ciarrocchi, "Approaches to Tumor Classification in Pulmonary Sarcomatoid Carcinoma," Lung Cancer (Auckland, N.Z.) 10 (2019): 131–149, https://doi.org/10.2147/LCTT.S186779 PMID: 31824199; PMCID: PMC6901065.

11. M. Mlika, F. Anjum, and F. El Mezni, "Pleuropulmonary Blastoma.[Updated 2023 Apr 27]," in StatPearls (StatPearls Publishing, 2025), 2024 Jan-, https://www.ncbi.nlm.nih.gov/books/NBK534211.

12. S. Van Loo, E. Boeykens, I. Stappaerts, and R. Rutsaert, "Classic Biphasic Pulmonary Blastoma: A Case Report and Review of the Literature," Lung Cancer 73 (2011): 127–132.

13. H. J. Lee, J. M. Goo, K. W. Kim, J. G. Im, and J. H. Kim, "Pulmonary Blastoma: Radiologic Findings in Five Patients," Clinical Imaging 28 (2004): 113–118, https://doi.org/10.1016/S0899-7071(03)00240-.

14. A. Bini, L. Ansaloni, G. Grani, et al., "Pulmonary Blastoma: Report of 2 Cases," Surgery Today 31 (2001): 438–442.

15. Q. Liu, F. Li, L. Wang, et al., "Pulmonary Blastoma With a Good Prognosis: A Case Report and Review of the Literature," Journal of International Medical Research 52, no. 6 (2024), https://doi.org/10.1177/03000605241254778.

16. R. J. Smyth, A. Fabre, J. D. Dodd, W. Bartosik, C. G. Gallagher, and E. F. McKone, "Pulmonary Blastoma: A Case Report and Review of the Literature," BMC Research Notes 7 (2014): 294.

17. T. K. Jain, H. Singh, R. Kumar, A. Bal, A. Sood, and B. R. Mittal, "Real Time F-18 FDG PET-CT-Guided Metabolic Biopsy Targeting Differential FDG Avidity in a Pulmonary Blastoma," Nucl Med Mol Maging 54 (2020): 261–263.

18. D. Brodowska-Kania, E. Kotwica, A. Paturej, et al., "What Do We Know About Pulmonary Blastoma?: Review of Literature and Clinical Case Report," Nagoya Journal of Medical Science 78, no. 4 (2016): 507–516, https://doi.org/10.18999/nagjms.78.4.507 indexed in Pubmed: 28008207.

19. K. Kim, S. Gupta, S. Gupta, P. Mittar, C. Minimo, and W. Tester, "Incidental Early Diagnosis of Biphasic Pulmonary Blastoma in a Patient With History of Stage IV Lung Adenocarcinoma," Thoracic Cancer 11, no. 10 (2020): 3029–3033, https://doi.org/10.1111/1759-7714.1362932833349.

20. S. T. Liman, T. Altinok, S. Topcu, et al., "Survival of Biphasic Pulmonary Blastoma," Respirology 100, no. 7 (2006): 1174–1179, https://doi.org/10.1016/j.rmed.2005.10.026 48. Kouvaris JR, Gogou PV, Papacharalampous XN, et al. Solitary 16332433.

21. Y. Xiu, L. Jiang, and W. Liu, "Classic Biphasic Pulmonary Blastoma With Brain and Axillary Metastases: A Case Report With Molecular Analysis and Review of Literature," International Journal of Clinical and Experimental Pathology 8, no. 1 (2015): 983.

22. I. Tsamis, S. P. Chachali, G. Gomatou, et al., "Pulmonary Blastoma: A Comprehensive Overview of a Rare Entity," Advances in Respiratory Medicine 89 (2021): 511–519.

23. C. S. Cutler, R. P. Michel, M. Yassa, et al., "Pulmonary Blastoma: Case Report of a Patient With a 7-Year Remission and Review of Chemotherapy Experience in the World Literature," Cancer 82, no. 3 (1998): 462–467, https://doi.org/10.1002/(sici)1097-0142(19980201)82:3<462::aid-cncr6>3.0.co;2-r, indexed in Pubmed: 9452262.

24. J. A. Lewis, W. J. Petty, J. Urbanic, et al., "Cure of Oligometastatic Classic Biphasic Pulmonary Blastoma Using Aggressive Tri-Modality Treatment: Case Series and Review of the Literature," Cureus 10, no. 11 (2018): e3586, https://doi.org/10.7759/cureus.3586 indexed in Pubmed: 30656089. 63.

25. R. Vila, J. J. McCoy, and R. E. McCall, "Pulmonary Blastoma, Report of a Case," Journal of the South Carolina Medical Association 69, no. 7 (1973): 251–256, indexed in Pubmed: 4515901.

26. T. M. Jenkins, J. J. D. Morrissette, J. C. Kucharczuk, and C. G. Deshpande, "ROS1 Rearrangement in a Case of Classic Biphasic Pulmonary Blastoma,"

International Journal of Surgical Pathology 26, no. 4 (2018): 360–363, https://doi.org/10.1177/1066896917749928 29295663.

27. Z. Meng, P. Chen, F. Zang, et al., "A Patient With Classic Biphasic Pulmonary Blastoma Harboring CD74-ROS1 Fusion Responds to Crizotinib," Oncotargets and Therapy 11 (2018): 157–161, https://doi.org/10.2147/OTT.S150001 29343973.

28. Z. Luo, C. Cao, N. Xu, et al., "Classic Biphasic Pulmonary Blastoma: A Case Report and Review of the Literature," Journal of International Medical Research 48, no. 10 (2020): 300060520962394, https://doi.org/10.1177/0300060520962394 indexed in Pubmed: 33107372.

29. J. Bosch-Barrera, F. Holguin, X. Baldó, et al., "Neoadjuvant Chemoradiotherapy Treatment for a Classic Biphasic Pulmonary Blastoma With High PD-L1 Expression," Anticancer Research 35, no. 9 (2015): 4871–4875, indexed in Pubmed: 26254381.

30. H. Larsen and J. B. Sorensen, "Pulmonary Blastoma: A Review With Special Emphasis on Prognosis and Treatment," Cancer Treatment Reviews 22 (1996): 145–160.